Tianjin Pharmaceutical Da Ren Tang Group (SHA:600329, SGX:T14) expects to post a net profit attributable to the parent of between 2.15 billion yuan and 2.39 billion yuan in 2024, soaring from 118% to 142% year on year, according to a Shanghai Stock Exchange disclosure on Monday.
The Chinese pharmaceutical company's attributable profit a year ago was 986.7 million yuan or 1.28 yuan per share.
The company attributed the forecast to a 1.71 billion yuan income generated from the disposal of a 13% stake in joint venture Sino-US Tianjin SmithKline Pharmaceutical.
Tianjin Pharma's shares rose less than 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.